IGF-1

Pharmacology

This entry is considered a group.

IGF-1 is a protein that in humans is encoded by the IGF1 gene. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges.

The polypeptide hormone IGF-1 is synthesized primarily in the liver upon stimulation by growth hormone (GH). It is a key mediator of anabolic activities in numerous tissues and cells, such as growth hormone-stimulated growth, metabolism and protein translation.

The compound (bioavailable peptide) version itself is divided into multiple types, such as standalone (amino acid portion), IGF-1 LR3 (highest half-life), IGF-1 DES, rhIGF-1, etc.

IGF-1 LR3 is considered the best form, with optimal half life and improved pharmacokinetics. Compared to other variants it is more expensive.

Note: IGF-I is not very stable and should be refrigerated and used within 2-4 weeks.

Intranasal Nootropic Efficacy

In one study of TBI, treatment with the 150mcg IGF-I significantly reduced the infarct volume by 63% vs. control (p=0.004), and improved all the neurologic deficit tests of motor, sensory, reflex and vestibulomotor functions (p<0.01). However, the 37.5mcg dose of IGF-I was ineffective. [1]

Human equiv. based on this study may be 300-500mcg IN, potentially best with ICOT.